Sir Run Run Shaw Hospital

Hangzhou, Zhejiang 310020

2 studies enrolling now · 18 studies all time

What they study most

Atrial Fibrillation, Breast Cancer, Breast Neoplasms, Cancer, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative, Congestive Heart Failure, Crohn's Disease, Esophageal Cancer, Essential Tremor, Locally Advanced or Metastatic and Unresectable HCC, Lung Cancer (NSCLC)

Studies at this site

• Pan Tumor Rollover Study — Recruiting now
• A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors — Recruiting now
• A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer — Running, not enrolling
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer — Running, not enrolling
• Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor — Completed
• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease — Running, not enrolling
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer — Running, not enrolling
• A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC — Running, not enrolling
• SyncAV Post-Market Trial — Running, not enrolling
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Running, not enrolling
• Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation — Completed
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC — Running, not enrolling
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors — Running, not enrolling
• A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC — Completed
• A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Stopped early